Skip to main content
Fig. 29 | Insights into Imaging

Fig. 29

From: Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review

Fig. 29

Axial T1-weighted MR obtained (a) pretreatment: image in late arterial phase shows hyperenhancement of a 2.5 cm LR-5 observation. b 6 months post stereotactic body radiotherapy (SBRT): image in portal venous phase shows persistent 7-mm nodular enhancement (arrow), perfusional anomalies (asterisk), and capsular retraction. c 1 year post SBRT: image in portal venous phase shows absence of nodular enhancement and persistent but decreased perfusional anomalies. The treated observation is categorized LR-TR Nonviable

Back to article page